Burning Rock
Burning Rock, Dizal Get Chinese Approval for Lung Cancer CDx
The test, approved by Chinese regulators in early 2022, is designed for the detection of multiple mutation statuses for nine genes.
Burning Rock, Bayer to Develop NGS-Based Companion Diagnostics in China
The companies will jointly develop next-generation sequencing-based companion diagnostic tests for Bayer's precision cancer therapies.
Burning Rock, Boehringer Ingelheim Ink Master Service Agreement for Oncology Companion Diagnostics
The companies will focus initially on Boehringer Ingelheim's MDM2-p53 antagonist, brigimadlin, now being studied in a new Phase II trial in China.
In Brief This Week: Datar Cancer Genetics, Daiichi Sankyo, ProPhase Labs, Innovent Biologics
News items for the week of Jan. 3, 2023.
Burning Rock Secures Lung Cancer NGS Test Regulatory Approval in China
The LungCure CDx next-gen sequencing kit is the company's second NMPA-approved in vitro diagnostic following a smaller six-gene panel commercialized in 2018.